Jersey City-based Organon recently announced a partnership with Sempre Health to motivate asthma patients to refill their prescriptions on time and improve adherence through an innovative cost-savings program.
The new program will enable eligible patients who refill their prescriptions on time and as prescribed for Dulera (mometasone furoate, formoterol fumarate dihydrate) and Asmanex (mometasone furoate) to receive discounts on their medications throughout the course of their therapy, with the aim of improving adherence to their medication.
Approximately 75% of patients in the U.S. struggle to take their medications as directed, and nonadherence to treatment is estimated to cost the U.S. economy between $100 billion to $300 billion a year. Under this innovative women’s health and technology partnership, eligible patients who refill prescriptions will have the opportunity to receive discounts on their medications throughout the course of their therapy, with personalized digital support that can improve adherence to their medication.
“This partnership represents a significant step forward in expanding access to medicines, and the ability to help eligible patients adhere to their treatments while also saving money is a winning contribution,” Ger Brennan, vice president and commercial lead, established brands, at Organon, said.
Through the program, patients can save more than $1,000 on their asthma prescriptions. This cost savings can help women and their families live a healthier every day, which aligns with Organon’s mission to improve the health of women throughout their lives.
